Lesional Psoriatic Epidermis Displays Reduced Neurofibromin Immunoreactivity  by Peltonen, Juha et al.
Lesional Psor~atic Epidermis Displays Reduced 
Neurofibromin Immunoreactivity 
Juha P eltonen, Seij a-Liisa Karvonen, * Heli YHi-Outinen, Outi Hirvonen, and Jaakko Karvonen * 
Department of Medica l Biochemistry, University ofTurku , Turku; and *D epartment of Derma to logy, University of O ulu , O ulu , 
Finland 
Neurofibromin enhances the inactivation of proto-
oncogene p21vas and has been suggested to function 
as a regulator of cell growth and differentiation. In 
normal skin, neurofibromin is particularly abundant 
in the basal keratinocytes of epidermis . The present 
study utilized antibodies raised against two synthetic 
peptides corresponding to different regions of neuro-
fibromin. One of the antibodies recognized all forms 
of neurofibromin and the other was specific for type 
II neurofibromin. The following specimens were an-
alyzed for neurofibromin immunoreactivity: 1) skin 
of apparently healthy volunteers, 2) active lesions of 
15 psoriatic patients, 3) apparently healthy skin of the 
same patients at the time of the active phase of the 
disease, and 4) the previously lesional areas after 
anti-psoriatic treatment of the same patients. The 
presence of neurofibromin mRNA in normal epider-
mis and in keratinocytes cultured from normal skin 
N e uro fibro min is e ncod ed by type 1 n e uro fibro ma-tosis (NF1) gen e , the muta ti o n s o f whjch have b e en Jjnke d with typ e 1 n e uro fibromato sis. N e u-ro fibro min contains a do m ain relate d to the GTPase activ a ting protein , which accele rates the 
inactivatio n of pro to -oncogen e p 21 rns. T hus, n euro fibro min is 
like ly to fun ction as a regulator o f ce ll g ro wth and diffe rentia tion , 
and ac ts as a tumo r suppressor prote in [1- 4] . Alte rnative spli cing 
results in the fo rm atio n o f diffe re nt isofo rm s of n e urofibrom in 
mRNAs (types I - IV) (S-7] . Fo r instan ce, type II n e uro fibro min 
mRNA contains an insertion of 63 ba ses in the G T Pase ac tiva t in g 
doma in of th e pro te in, whj ch is absent fi·om type l n e urofibromin 
mRNA . Our recen t studies h ave d e m o n strated that n o rmal basal 
keratinocytes express type II n e urofibromin a t a hi gh level [8]. ln 
n o rmal e pide rmis, mitoses are res tri c ted to th e basa l cell laye r [9] , 
and apparently n e uro fibro min pl ays an impo rtan t ro le in the 
regul atio n o f ce ll pro life ratio n o f th ese cell s [8]. 
Psori asis is c h arac te ri zed by prolife ratio n and abn o rmal diffe re n-
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was demonstrated by reverse transcriptase-poly-
merase chain reaction or by Northern hybridization. 
In marked contrast to normal epidermis, active pso-
riatic lesions were characterized by a weak immu-
nosignal for types .I and II neurofibromin in the basal 
cell layer of the epidermis. Previously lesional, clin-
ically healed areas displayed variable, yet clearly 
detectable, expression of neurofibromin. Our results 
demonstrate that the epidermis of psoriatic lesions 
displays reduced immunostaining for type I and II 
neurofibro1nins compared to normal epidermis, and 
that neurofibromin immunoreactivity is partially re-
stored concomitant with clinical healing of the lesions. 
The question whether the changes in neurofibromin 
expression in psoriasis are causal or consequential with 
respect to the pathogenesis of psoriasis remains to be 
elucidated.] Invest Demrato/105:664-667, 1995 
tia t ion o f e pide rmal cells [1 0 , 11] . Psoriasis is a chronic and re lapsing 
di sease that varies in its seve ri ty and age o f o nset. Both gen eti c 
predisp ositi o n and e n viro nme ntal fa c to rs play a role in the patho-
gen es is o f psoriasis but the m o lecul ar m ech anism s leading to the 
develo pme nt o f psoriasis are poorl y unde rstood [1 2, 13] . 
T h e purpose o f thi s study w as to assess the express io n of 
n e u rofibro min in active psoria t ic les io ns to estimate its p o tential 
ro le in the pathogenesis of the di sease. Furth e rmo re , our expe ri-
m e ntal design included assessing the express io n o f n e uro fibro min 
afte r an ti-psoriati c treatment in clinica ll y h ealed, pre viously les ional 
p soriasis epidermis utilizing an tibodies reco g niz ing type I and type 
II n e uro fibromin s. 
MATEIUALS AND METH ODS 
Patients A total of 1 5 patients with pso ri asis was included in the present 
study (11 male and 4 fe male, ages 15-62 years) . All pa tients had moderate 
to severe plaque- type or c•·ythrodermic psori asis. T he duration of pso ri asis 
ranged from 3 to 30 years. 
Tissue Specimens 
Actil' c Psorinsis Lesions nnd Pcrilc:s iollnl Skin : N o ne of th e pati ents anal yzed 
in this group had used an y topical anti-psoriati c treatment other than 
emollients for 6 months or more. O ne of these pa tien ts had rece ived 17.5 
mg/weck of methotrexate for arthropathic psoriasis, bu t o thers had had no 
systc n1i c an ti-psoria tic trcat111Cn t. l3 efo rc treatn1cot, 4-rn ln punch o r exci-
sion biopsies were ta ken !i·om 12 pati ents bo th fi·om untreated lesional skin 
and from peril es ional comple tely hea lthy looking skin. The same patients 
were subsequently treated with bath-psora len plus ultraviolet A (UV A) or 
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Figure 1. Down-regulation of type II neurofibromin expression in a psoriatic lesion. A bio psy covering both lesio nal (o n th e left) and peril esional 
(on the ri ght) skin was excised before treatment of the patient and subjected to indirect immuno Au o rescence labeling with antibod y 67, w hich recogni zes 
selectively type II ne urofibromin (see Mnterin ls n11d Methods). Staining is seen in the basal ce ll layer of the peri lesio nal epidermis. but not in the adjacent lesio nal 
e pidermis. Scale bnr, 100 (l.m. 
UV'B combined with dithranol , top ical steroids. or to pical calcipotriol 
ointment and two patients with to pica l t reatm ent o nly. 
T iss11e Speci111e11 s.Jim11 Cli11icnlly H ealed, Prc11iclllsly L esio11nl Ski11: Seven of the 
pa tients were rcbio psicd 3 to 10 wee ks after an ti-psoria t ic rrcatn1cn t, \vhcn 
the psoriasis was totall y o r partially in remissio n . The rebiopsy was alwa ys 
taken from clinicall y healed, previously lcs io nal skin . From three patients, 
biopsies were taken on ly after th erapy from treated , improved , previo usly 
lesional skin and peril es io nal healthy looking skin. 
Co 11trol Ski11 Sn111plcs: O ne 55-year-old man and two w o m en , 26 and 36 
years o ld , having no personal o r fami ly hi story of psoriasis, se rved as 
con tro ls fo r inlnlunoh.istochcnlica l studies. Skin san1pl cs fron1 two fcn1a lc 
patients, 34 and 46 yea rs o ld , were used for isolation of epidermal RNA and 
in itiation of keratinocyte cul tures . 
Antibodies Immunohistochemical anal yses w ere carri ed out using ne u-
rofibromin-specifi c antibodies raised in rabbits aga inst synthetic peptides as 
d escribed in de tail earlier [8]. In brie f, peptides used in this stud y were P84, 
seq u ence GSASQYQKQRSAGSFKRNS IKK IV (amino ac id sequence 
2795- 2818 in j1]) ; and P67, sequence C HSLLNKATYKE.KK.ENKKS . 
corresponding to 19 amino acids fro m the alte rnatively spliced 21 - amino 
acid domain between amino acids '13 70 and 13 71 [1.5] . Pep tides were 
synthesized with an auto mated peptide synthesize r (Applied Biosys te m s 
43 1A, San Diego, CA), using O.lmmol Fmoc/ NMP strategy. The peptides 
were purifi ed with preparative reversed-phase high-perfo rmance liquid 
c h romatograp hy (Applied 13iosystem s, M odel 151 A Peptide Separation 
System). Peptide identi ty and purity were confirmed using mass spectrom-
etry and high-performance liquid chromatography as desc o; bed [8]. New 
Zealand White rabbits were immunized with the pep tide as desco;bed 18 ] . 
Affinity purification of the antise ra was ca rried out using the appropria te 
p ep tide coupled to cyanogen bromide-ac tivated C H-Sepharose (Pharmacia , 
Uppsala , Sweden) [8,14]. 
Indirect Immunofluorescence Labeling Frozen sectio ns, 5- 7 (l.m 
thi ck, were cut on silana ted glass slides . Prior to immuno labeling , the 
sectio ns w ere fixed in 100'!1,, e thanol at -20°C for 10 min , rehydrated fo r 1 
min in 95% and 70°/o, e th ano l at room temperature, and balanced in 
p h osphate-buffe red saline (PBS) for 5-10 min. To prevent non-specifi c 
a n ti body binding, the sarnplcs were incubated w ith I 1Xr bovine sc rurn 
albumin in PI3S for ·15 min. Primary antibodies were appropriate ly diluted in 
PBS-albumin , and the samples were exposed to the antibodies for 1 h at 
roo n1 tcn1pcratu rc. o r ove rnight at 4° . The specirncns were \Vas hcd in PllS 
at roo m temperature fo r l h with fi ve changes and subsequently incubated 
with tetram eth yl-rhodamine iso thiocyana te- conjugated swine anti-rabbit 
JgG (Dako A/S, G los trup, Denmark). !3oth antisera and aftinity-purifoed 
antibodies were used in immunolabelings. the main findin gs being essen-
tia ll y the sa m e. The samples were o bse rved and photographed with a Leitz 
A ri stoplan microsco pe equipped with an epiilluminator , fi lte rs fo r tetram-
eth y lrhodamine isothiocyanate Au orescence, and camera attachment. 
Control lmtnunorcactions Control intntuno rcactio ns included the fo l-
lowing: 1) primary antibodies were omitted. 2) primary antibodies were 
rep laced with 1 'Xr bov ine serun1 albumin in PBS, 3) prinwry antibodies were 
r e placed with preimmune rabbit sera diluted ·1 :50 in PI3S, and 4) primary 
antibodies were preabsorbed with I OX m o lar excess of synthetic peptide 
that was o ri ginall y used for in1n1L111iz ati o n [81. In all contro ls, a f.,int uni fo rm 
b ackground Auo rescence o nly was o bse rved. 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
R.N A w as extrac ted from epidermis o f skin samples o btained fi·om a con tro l 
patient undergo ing surge ry for cosn1 e ti c rea sons. To separate cpidcrntis 
from denn is, ti ss ue sample was detacloed enzymati ca ll y by incubating the 
specimen overnight in a so lution containing 0.17% trypsin (T-8918 , Sigm a, 
St. Louis, M O ). 30 mM HEPES, 10 mM glucose . 3 mM KCI. 130 mM 
NaCI, and 1.0 mM Na2 HPO .,. Human kcratinocytes were grown in 
serum-free low-ca lcium (0. 15 mM) kcratinocyte g rowth m edium (Cio net-
ics Corp .. San Diego, CA). 
To tal RNA was iso lated using an ac id guanidinium isothiocyanate-
chlorofo rm- pheno l extraction [8] and was tra nscribed into single-stranded 
DNA in 20 f.LI reac tion containing 9.5 U AMY reverse transcriptase 
(Pro m ega. Madison . W I) . AMY R T reaction bu fFer (50 mM Tris-HCI. pH 
8.3, 50 mM KC I. 10 mM MgC I2 • I 0 mM d ithio lthre itol, 0 .5 mM spermi-
dine) , 0.5 mM of each dcoxynucleotide, 60 pmol rando m hexamers . and 20 
U of RNasin (Prom ega). T he reacti o n was allo w ed to proceed a t 42°C for 
60 min. For PC R., I fl. I of the R T reactio n product was used as a te mplate 
in a l 0 f.LI reactio n con ta inin g 20 pmo l neurofibromin speciti c sense and 
an tisense o ligonucleotide primers. 5 '-GAGTTTGATCAACGAA TTCTT-
TATG-3 ' (primer A in llSJ) and 5 ' -TGGCTCTGCAGTGCAGGAGGG-
TAAG-3 ' (p rim er B [I S]), 0 .2 mM of each dcoxynuclcotide. 1 U Dynazyme 
(Thermus brocki anus. Finnzym cs Inc ., Espoo, Finland ) in buffer w ith I 0 
mM T ri s-H C I, pH 8.8. 50 mM KCI, 1.5 noM M gCI2 • and 0. 1% Triton 
X -1 00. T he concentratio n of MgCI2 was rai sed to 2.5 mM with 25 mM 
MgC I2 . Amp li fi ca ti o n was pe rfo rm ed by incubating the mix ture for 30 
cycles of denaturation (60 seconds at 94 °C), annea ling (60 seconds at 65 °C) 
and extensio n (60 seconds at 72 °C). In the negative con tro l sam ples, the 
templa te w as o mitted and PC R was perfo rm ed in the sa m e condi ti o ns as 
other samples. T he PC R products were analyzed clectrophoreticall y o n 3% 
agarose gels (2% NuSicve GTG and I% Seal< em GTG agarosc . FMC Corp .. 
R ockland , M E) and sta ined w ith e thidium brom ide . 
Northern Transfer Analysis RN A iso lated from cultured keratinocytes 
was frn c tio natcd 0 11 0. 91Yo agarosc ge ls under denaturing conditi o ns and 
t r<l n sferrcd to n ylo n 111 Cn1bran c (B iodync lll Cinbran c. Pa ll Biosupport. East 
Hills, NY) . The neurofibromi n-s pecifi c eDNA pro be 18J was rad io labeled 
w ith e2 P.!dCTP (3000 C i/ nnno l: D u Pont, 13 oston . MA) by random 
priming to a specific activ ity o f at least 5 X 10" cpm/ (l.g (Ra ndo m Primed 
DNA Labeling Kit, Boehringer Mannheim . Ind ianapoli s. IN) . T he fi lters 
were prehybridized and subsequentl y hybridized wi th the eDN A in so lu tion 
con tai ning 50% fonnamide . 50 mM sodium phosphate (pH 6.5). 0.1 % 
sodium dodccylsul fate. 5 X standard sa line c it rate (SSC : I X SSC = 0. 15 M 
sod iu m chlo ride/ 15 mM sodium citrate), 5 X Den hardt' s so lution, and 250 
(l.glml calf thymus DNA. Follo win g hybridizatio ns for l S-24 h at 42°C, th e 
filters w ere was hed to a final sn·ingcncy ofO.I X SSC/ 0 .1 % SDS at 52°C. 
R ESULTS 
Immunolocalization of Neurofibromin in Healthy Control 
Skin and in Perilesional E pidermis of Psoriasis Patients 
Indire c t immun o flu o rescen ce sta ining of con tro l skin with antibody 
67 and antibody 84 gave res ul ts that were in good agreement w ith 
e arlier findin gs 18]. In bri ef, antibody 67, recogniz ing exclusive ly 
type II n e urofi bro min , d ecorated th e basa l ke ratinocytes . a n d 
antibody 84 , whic h recognizes both type I and II n e uro fib romins, 
labeled all laye rs of e pide rmis . Appare ntl y h ea lth y p e ril es ional skin 
of p soriatic patie nts gave essen t iall y the sam e results as contro l skin 
(Figs 1 and 2). R T -PC R d e m onstra te d th e presen ce of n e urofi-
bromin mR . .NA in n o rmal epide rmis and in k eratinocytes c ulture d 
fi·o m n o rma l human skin . Northern transfer analysis was utilized to 
d e monstrate th e presen ce of n e urofibr o min mRNA in c ultures 
initiated fi·om n o rmal skin (sec b e low). 
Neurofibron~in in Untreated, Active Psoriasis Lesions In 
marke d contrast to h e althy, o r p e ril e sional e pidermis , active les io n s 
of p sori asis p atients w e re c h arac te rized with very w ea k immuno-
stajning for type I and for typ e II n e urofi bro min s in the basa l ce ll 
666 Prt 1 ONI /, r ,t/ 
Figure 2. Immunolabellng with antibody 84 demonstrates the 
reduction of aU forms of neurofibromln in the ba al ceU layer of 
active psoriatic lesion,. Tissue spenmem from apparent!) beald1y 
cpidenni~ of a p)uria\i\ paricnc (n) and from an active p\oriatic lc~ion (b) 
were subjected to mdircct unmunoftuorc)ccnce labeling with antibody !14, 
winch rcco~:;nizc• cpitope~ that arc pre,;.,nt in all form\ of neurofibrormn 
{<cc Ham'ials a110l \lrrho•.h) Tlill antibody dccoratcJ the "ntir" cpidermi~ of 
penlc"onal <kin . In contrn,t, onl)· very weak )tairung for ncurofibromm can 
be \ecn in the hasal cells of ch~: psoriauc lelional epidennis. Scn/r lrnr, 1 on 
J.l.lll 
Ia) er of the cpidermi (Figs 1 and 2). The finding~ were constant 
in all cases studied. 
Neuro6brom.in in ClinicaUy Healed, Previously Lesional 
Epidermis The cxprcs\ion of neurofibromin wa~ also asscS\cd 
after anti-p,oriaol rrearment of the patients and clinicaJ healing of 
the lesions. nte result\ demonstrated considerable variation ill 
findings on differtnt panenrs as illu\trated in Figs 3a-c. In ,urn-
mary, immunolaheling for ncurofibromin revealed that previously 
le<ionaJ areas di,played variable. yet clearly detectable, expres ion 
of neurofibromin (Fig 3). 
Identification ofNeurofibromin mRNA in Normal Human 
Epidermis and in Cultured Keratinocytes R T -PCR demon-
srrared the pre~encc of neurofibromill mRNA ill normal epidem1is 
and ill culturt.>d keratinoC) tc (Fig 4a). Specifically. the use of 
ohgonucleoride primer~ de~ignated A and B by Wallace rl a/ [15] 
resulted in the amplification of characteristic 409-bp cDNAs. RNA 
i~olated from rulrured keratinocyre~ \\ .1s ill funher anaJy e~ sub-
jected to Northern blot hybridizations. The neurofibromin-specific 
eDNA probe hybriilized to a characteristic transcript of very large 
size (Fig 4b), which is comi~tcm with earlier studies repornng a 
13-kb size for neurofihromin mRNA [8.15]. 
Dl CUSS10N 
Mutations in Nfl gene cause type I neurofibromatosis (von 
Rccklmghamcn's di:.ea~e) .. 1 genetic neurocutaneous syndrome 
'' ith autosomal dominant mheritancc (for re\ iews ~ce [ 16,171), but 
mutations of the NFI gene have also been found in other disease~ 
in addition to neurofibromatosis. For instance, omatic mutaoom of 
the NFl gene have been detected in certain malit.,rnancies. such a\ 
anapla\tic 3\CCOC) toma and malignant myeloid disorder\ r 18-211[. In 
these cases. the lcveh of neurofibromin protein and/or neurofihro-
min mRNA haw been reduced in the n:s1dent cells of the involved 
ti\SUe~. 
Epidermal ker..Hinot > tes have previou\ly been sho'"" tO e:--press 
neurotibromin [ H,21] and, more specifkally, type II neurofibromin 
is preferentiall} c:~.pre\sed in the basal cell layer of the normal 
epidermis [8) . This rumor-suppressor protein m:t) thus act .1s a 
regulator of proliferation in these cell~. 
1111. JOURN-\l OF IN\E.STf(,.o\TIVE l)fR.M.'\TOLOGV 
Figure 3. Variable expression ofneurofibromin after anti-psoriatic 
treatment in previously lesional epidermis. Punch bropsic< were taken 
from three patient\ (u-r) 4 weeks after the initi<Lrion of anti-pmriatic 
trcanncnt. 1l1e ~amples "ere 'ubjcctcd ro md1rcct immunoftuore>ecncc 
lahding with dncihod)' 67 (\CC Mn11•rials mullllt•tltctcls). Srnlr bnr, 100 /Lffi. 
In our scudy. basal keratmocytcs of active psonasas lesions 
di~playcd onl} barely detectable immunmtaining for both C)'PC I 
and II neurofibromim. lr is thus tempting to speculate that the 
reduction of neurofibromill e'\pression by the basal kcrarinoC)'tes in 
lc\iom of psoria~is may play a role in the cascade of events leading 
to unconrrollcd proliferation of keratinocyce~ and to the develop-
mcnr of the psoriatic lesions. This notion is further \upported by rhe 
finding that clillical heaJing of the lesions was accompanied by a 
partial restoration of oeurofibromin immunorcacuvit). The pre~ent 
re,ults are not sufficiem , however, to sugge\t whether the altered 
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Figure 4. Neurofibromin mRNA is expressed in normal human 
epidermis and in cultured keratinocytcs. a) Total RNA was extracted 
from <"pidcnnis of nonnal ~kin or from cultured human kcratinocyrcs and 
was 'ubjceted to R T -PCR. applying specific- prim en for ncurofibromin (sec 
.Hatmals nrrd ,\,/rl/ro<ls). Larrf I. the cpidenni~ of nonual skin was detached 
cnzymaucall}' h) incubating tbc tissue specimen ovcmight in a solution 
comaimng 11.17%• trypsin, 30 mM HEPES, 10 mM glucose, 3 mM KCI. 130 
mM NaCI Jnd 1.() mM Na2 HP04 • and total RNA was isolated using the 
guanidine isothioc-yanate extraction method. Larrr 2. human kcratinocyrcs 
were gto\l.n 111 'crum-frcc low-c-alcium (0.15 mM) kerarinoqte growth 
medrum for -18 h prior to RNA isolation. The PCR products were separated 
on J".,, agarow gd. which was subsequcmlr naincd widt edtidium bromide. 
b) Norrhcm tran,fcr anal)·sis of RNA rsolated from cultured kcratinocytcs 
was carried om u>ing a ncurofibromin sequence-specific eDNA that 
hybridized · to a 13-kb transcript (sec M,ll~ri<Jis arrd Mt•tlrtJds). 
neurotibromin expression might be causal or consequential. Be-
cau~c no evidence suggests mutations in NFl gene in p~oriasis. we 
propmc that factors other than mutations in the NFl gene may 
locally down-regulate the e~pression of neurofibromin, and that 
thls down-regulation may play a role in the pathogenesis of human 
disea~cs. To date. however. molecular mechanisms regulating the 
rranscripnon of the NFl gene, and thus dererminjng the levels of 
the NFl mRNA and neurofibromin within cells, arc virtuaUy 
unknown. Our finding~ )uggc\t that reduced level' of ncurofibro-
mjn in basal keratinocytes may be an importam factor in rhe process 
leading to excessive proliferation of kcratinocytc\ in psoriasis. 
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